Case | Gender | Follow-up (months) | Age (years) | Treatment | Clinical evaluation | Maximum thickness of BM (µm) | Villous atrophy | IEL (per 100 enterocytes) | Epithelial detachment | LP vessels entrapped in basement membrane |
---|---|---|---|---|---|---|---|---|---|---|
1 | F | Baseline | 77 | 14 | Subtotal | 12 | >10% of surface | Present | ||
11 | Budesonide | No improvement | 21 | Total | 10 | <10% of surface | Present | |||
18 | 6-MP | Small improvement | 18 | Total | 12 | >10% of surface | Present | |||
40 | Budesonide and 6-TG | Improvement | 2 | Mild | 6 | <10% of surface | Absent | |||
2 | M | Baseline | 79 | 34 | Total | 10 | 100% | Present | ||
9 | Budesonide and 6-TG | Improvement | 32 | Total | 24 | 25–50% | Present | |||
30 | Budesonide and 6-TG | Improvement | 21* | Subtotal | 14 | >50% | Present | |||
3 | F | Baseline | 88 | 21 | Total | 12 | >10% of surface | Present | ||
10 | Budesonide and 6-TG | Improvement | 2 | None | 4 | Absent | Absent | |||
4 | F | Baseline | 76 | 19 | Total | 32 | <10% of surface | Present | ||
3 | 6-TG | Improvement | 23 | Total | 14† | >10% of surface | Present |
*Very focal. †Also some intraepithelial eosinophils.
6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; BM, basement membrane; F, female; IEL, intraepithelial lymphocytes; LP, lamina propria; M, male.